FINWIRES · TerminalLIVE
FINWIRES

調査速報:オールステート:引受業務の好調さが第1四半期のEPSの大幅な予想上回りを後押し

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。ALLは、第1四半期の営業利益(EPS)が前年同期の3.53ドルに対し10.65ドルとなり、当社の予想6.85ドル、市場コンセンサス予想7.24ドルを上回りました。好調な業績は、引受業務の改善によるものです。第1四半期の売上高成長率は3%で、当社の予想4~8%を下回りましたが、損害保険の既収保険料は5.5%増加しました。コンバインド・レシオは、災害損失が44%減少したことで、97.4%から82.0%に改善しました。災害損失を除く実質コンバインド・レシオは、83.1%から80.3%に改善し、これまでの料率引き上げの成功を裏付けています。ALLの広範なリストラ戦略の一環として最近行われた、企業向け任意給付事業の20億ドルでの売却により、中核事業である損害保険事業への再投資のための資金が確保されます。 ALLは、特に自動車保険分野における競争激化が予想されるにもかかわらず、価格規律を維持すると見込んでいます。同社の堅調な引受実績は、不利な保険金請求傾向に対処するために実施された積極的な料率引き上げの成功を証明しています。4月30日の電話会議における経営陣の価格見通しを楽しみにしています。

Related Articles

Asia

Electro Optic Systems Reports Contract Backlog Growth as of March 31

Electro Optic Systems Holdings (ASX:EOS) reported a contract backlog of AU$518 million as of March 31, up 13% from the end of 2025, according to a Thursday filing with the Australian bourse.The company closed the March quarter with unrestricted cash holdings of AU$95.1 million, representing a decrease of AU$11.8 million from the end of 2025, per the filing.

$ASX:EOS
Asia

Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance

Regis Healthcare (ASX:REG) said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit (RAD) cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.

$ASX:REG
Research

Research Alert: CFRA Keeps Hold Opinion On Shares Of Mondelez International

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $63, raised $1, reflects a 19x multiple of projected 2027 EPS, in line with MDLZ's historical forward P/E average. We raise our 2026 EPS estimate by $0.06 to $3.08, but cut 2027's by $0.11 to $3.32. We continue to see headwinds related to chocolate and biscuits divisions, though favorable forex has been helping to a degree. MDLZ highlighted plans to stimulate growth with more promotional activity, which could boost revenues (we see an acceleration in revenues in 2027), but may come with the trade-off of narrower margins. We note that cost-saving efforts can also contribute to staving off some of the margin pressure. MDLZ is largely hedged on its cocoa input costs for 2026 but less so in 2027. Thus, if the substantial rise in cocoa pricing in 2025 does not reemerge, it should help the bottom line in 2027 as cost pressures should ease. Share buybacks have also contributed to EPS, and we note that Q1 2026 share count was down 1.5% from one year earlier.

$MDLZ